Epstein-Barr virus reactivation plus immunotherapy for recurrent nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Infections, Mouth & dental clinical trials.
This trial tests a combination of a drug that reactivates the Epstein-Barr virus (EBV) in the body plus an immunotherapy drug (PD-1 antibody) for people with nasopharyngeal cancer that has returned or spread. The goal is to see if this combination can help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have nasopharyngeal cancer (a type of head and neck cancer) that has come back or spread to other parts of the body.
- Your blood must show signs of the Epstein-Barr virus (EBV), which is a common virus that can be present in some patients.
- You must be between 18 and 75 years old.
- You must be in relatively good health, able to take care of yourself, and able to walk around (ECOG 0-1).
- Your blood counts and organ function (liver, kidneys, etc.) must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an EGFR antibody, a PD-1 inhibitor, and chemotherapy for people with nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this new mix can help shrink tumors or slow the disease.
This trial tests a combination of chemotherapy and immunotherapy (pembrolizumab) given before and after surgery for nasopharyngeal cancer that has come back locally. The goal is to see if this approach can control the cancer and improve outcomes for patients who can't have standard re-treatment.
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
This trial tests whether giving an immunotherapy drug called adebrelimab, based on levels of EBV DNA in the blood, can help people with advanced nasopharyngeal cancer. It is for those who have finished initial chemotherapy and still have signs of the virus or stable disease.
This trial tests a new combination of treatments—a targeted drug that delivers cancer-killing medicine directly to tumor cells, an immunotherapy that helps your immune system fight cancer, and standard chemoradiation—for people with advanced nasopharyngeal cancer. The goal is to see if this combination works better than standard treatment alone.
This trial tests a combination of two drugs, tislelizumab and capecitabine, for people with nasopharyngeal cancer who still have detectable EBV DNA in their blood after finishing radiation therapy. The goal is to see if this treatment can help clear the virus and improve outcomes.
Hear when a new Nasopharyngeal Cancinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.